Abby Hardy, Author at BioTuesdays

Developments

HLS Therapeutics to launch Vascepa in Canada next month

HLS Therapeutics (TSX:HLS) reported that its cardiovascular drug, Vascepa, will be available in Canada on or about February 18, 2020. Vascepa was approved by Health Canada at the end of 2019. HLS noted that the approval...

January 28, 2020

Developments

Akcea reports positive topline Phase 2 data from cardiometabolic disease trial

Akcea Therapeutics (NASDAQ:AKCA) reported positive topline results from its Phase 2 study of AKCEA-ANGPTL3-LRx in patients with hypertriglyceridemia, Type 2 diabetes (T2D) and non-alcoholic fatty liver disease (NAFLD). ...

January 28, 2020

Feature

Inagene personalizing pain management with comprehensive genetic test

Closely-held pharmacogenetics company, Inagene Diagnostics, aims to replace the “trial-and-error” approach to pain management with a comprehensive genetic test that helps physicians provide personalized pain management...

January 28, 2020

Markets

Dawson James ups CollPlant PT to $15 from $9

Dawson James Securities raised its price target for CollPlant Biotechnologies (NASDAQ:CLGN) to $15 from $9, reflecting an “increase in valuation, which translates into less dilution in terms of our assumptions around...

January 27, 2020

Developments

Imagin Medical reports upcoming 2020 milestones for i/Blue Imaging System

Imagin Medical (CSE:IME; OTCQB:IMEXF; Frankfurt & Stuttgart Symbol:DPD2) reported its 2019 i/Blue Imaging System development achievements and upcoming 2020 milestones. “2019 was a momentous year for the Company as...

January 23, 2020

Developments

Genprex gets fast track designation for lung cancer gene therapy

The FDA granted fast track designation for Genprex’s (NASDAQ:GNPX) Oncoprex immunogene therapy in combination with osimertinib for the treatment of non-small cell lung cancer (NSCLC) patients with epidermal growth...

January 21, 2020

Developments

Aldeyra enrolls first patient in Phase 3 allergic conjunctivitis trial

Aldeyra Therapeutics (NASDAQ:ALDX) enrolled the first patient in its Phase 3 INVIGORATE trial of topical ocular reproxalap for the treatment of allergic conjunctivitis. The trial will enroll some 120 patients to assess...

January 21, 2020

Developments

Tyme Technologies doses first patient in Phase 2 sarcoma trial

Tyme Technologies (NASDAQ:TYME) dosed the first patient in its HopES Phase 2 trial evaluating SM-88 for the treatment of high-risk sarcomas. SM-88, or racemetyrosine, is a modified tyrosine derivative designed to...

January 16, 2020

Developments

Kala Pharma completes enrollment in Phase 3 dry eye disease trial

Kala Pharmaceuticals (NASDAQ:KALA) completed enrollment in its STRIDE 3 Phase 3 clinical trial of EYSUVIS for the short-term treatment of dry eye disease. The trial’s inclusion/exclusion criteria have been modified from...

January 15, 2020

Developments

Mereo BioPharma reports additional positive Phase 2b setrusumab data

Mereo BioPharma (NASDAQ:MREO) reported additional data from its Phase 2b ASTEROID clinical study of setrusumab in adults with Type 1, 3, and 4 osteogenesis imperfecta (OI). OI, also known as brittle bone disease, is...

January 14, 2020

Author - Abby Hardy

HLS Therapeutics to launch Vascepa in Canada next month

Akcea reports positive topline Phase 2 data from cardiometabolic disease trial

Inagene personalizing pain management with comprehensive genetic test

Dawson James ups CollPlant PT to $15 from $9

Imagin Medical reports upcoming 2020 milestones for i/Blue Imaging System

Genprex gets fast track designation for lung cancer gene therapy

Aldeyra enrolls first patient in Phase 3 allergic conjunctivitis trial

Tyme Technologies doses first patient in Phase 2 sarcoma trial

Kala Pharma completes enrollment in Phase 3 dry eye disease trial

Mereo BioPharma reports additional positive Phase 2b setrusumab data

Subscribe